Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents

Lichuan Wu1,*, Guizhen Wang2,*, Shuaibing Liu1,*, Jinrui Wei3,*, Sen Zhang1, Ming Li4, Guangbiao Zhou2 & Lisheng Wang1

Matrine, an active component of root extracts from *Sophora flavesens Ait.*, is the main chemical ingredient of Fufang Kushen injection which was approved by Chinese FDA (CFDA) in 1995 as an anticancer drug to treat non-small cell lung cancer and liver cancer in combination with other anticancer drugs. Owning to its druggable potential, matrine is considered as an ideal lead compound for modification. We delineate herein the synthesis and anticancer effects of 17 matrine derivatives bearing benzo-α-pyrone structures. The results of cell viability assays indicated that most of the target compounds showed improved anticancer effects. Further studies showed that compound 5i could potently inhibit lung cancer cell proliferation *in vitro* and *in vivo* with no obvious side effects. Moreover, compound 5i could induce G1 cell cycle arrest and autophagy in lung cancer cells through up-regulating PI3K/Akt/mTOR pathway. Suppression of autophagy attenuated 5i induced proliferation inhibition. Collectively, our results infer that matrine derivative 5i bears therapeutic potentials for lung cancer.

Lung cancer is the leading cause of cancer-related death, which has ranked first in men and second in women in morbidity and mortality1. Currently, chemotherapy is the main treatment of lung cancer2. Although the survival of lung cancer patients has been improved with the emergence of tyrosine kinase inhibitors3,4, there still comes with new issues, such as drug resistance. It is of significant need to develop novel drugs to improve lung cancer patient outcomes.

Matrine, extracted from roots of *Sophora Flavescens Ait.* is the main chemical ingredient of Fufang Kushen injection which was approved by Chinese FDA (CFDA) in 1995 as an anticancer drug to treat non-small cell lung cancer and liver cancer in combination with other anticancer drugs5–10. Recently, considerable literatures have reported that matrine has promising anticancer activity11. Besides, due to its druggable advantages, such as flexibility structure and good safety profiles, matrine is considered as an ideal lead compound for further modification12–15.

In our previous study16, 19 matrine derivatives were synthesized and derivative 6i showed the strongest anticancer effects towards A549 lung cancer cells *in vitro*. However, 6i displayed obvious toxicity in the *in vivo* mouse model. In the present study, in order to obtain compounds with potent anticancer effects and low toxicity, we used matrine as a lead compound to synthesize 17 matrine derivatives bearing benzo-α-pyrone structures which are a group of compounds including flavonoids and coumarins and could improve the pharmacological activity of compounds17. Further, the anticancer effects of these 17 matrine derivatives were screened and the anticancer mechanism of compound 5i was investigated.

1School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi 530004, PR China. 2State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. 3Guangxi Scientific Research Center of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi 530200, PR China. 4Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, People’s Republic of China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to G.Z. (email: gbzhou@ioz.ac.cn) or L.S.W. (email: w_lsheng@163.com)
Results

Cytotoxic activities of matrine derivatives. The synthetic route for benzopyrone matrine derivatives is outlined in Fig. 1 and depicted in Methods and supplementary information. All the available derivatives were evaluated for their cytotoxic activities against four human cancer cell lines, including A549 (lung cancer cell), MCF-7 (breast cancer cell), SGC-7901 (gastric cancer cell) and Bel-7402 (hepatocellular cancer cell) (Table 1). Most of the derivatives exhibited improved anticancer efficacies with IC_{50} 15~484 times lower than that of matrine. Compound 5c, 5f, 5g and 5i showed better anticancer effects than other matrine derivatives. The anticancer effectiveness of the original matrine compound and these four derivative compounds were ordered as follows: 5i > 5c > 5g ≈ 5f > matrine. Compounds 5c and 5i have the same substituent group 6′,8′-di-tert-butyl in benzopyrone structure. Compound 5i is the N-oxidation product of 5c. It suggested that the substituent group 6′,8′-di-tert-butyl in benzopyrone structure and N-oxidation could both improve anticancer effects. It also can be found that 6′,8′-di-tert-butyl group showed better anticancer effects than 6′-bromo or 6′-chloro group in benzopyrone structure. Considering the favorable cytotoxic activities of compound 5i and lung cancer morbidity and mortality, we chose compound 5i as the representative compound for further investigation on lung cancer model.

Compound 5i inhibits lung cancer cell proliferation and colony formation. To detect whether 5i treatment could inhibit cell growth in lung cancer cells, cell viability assays were performed in lung cancer cells (Fig. S1). H1975, H460, and A549 were the most sensitive cell lines to compound 5i. Furthermore, the results showed that 5i potently inhibited cell growth in a time- and dose-dependent manner in the tested cell lines (Fig. 2a, Fig. S2a). The IC_{50} at 48 hours for A549, H460, and H1975 was found around 8, 6, and 5 μM, respectively. Therefore, we used 4 μM (around IC_{50}) of 5i in the following studies. The colony formation results demonstrated that 5i significantly inhibited lung cancer cell colony forming activity (Fig. 2b, Fig. S2b).

Compound 5i induces G1 cell cycle arrest in lung cancer cells. To further define the anticancer effects of 5i on lung cancer cells, we conducted cell cycle analysis in A549, H460, and H1975 cells. Cells were treated with different concentrations of 5i for 24 hours. The results displayed that 5i arrested cell cycle of H460 and A549 at G1 phase in a dose-dependent manner (Fig. 2c). The percentage of G1 phase in H460 cells increased from 43% (control) to 57% (4 μM, p = 0.04) and 64% (6 μM, p = 0.01), respectively (Fig. 2c, left). Consistently, the percentage of G1 phase in A549 cells increased from 49% (control) to 63% (4 μM, p = 0.02) and 68% (6 μM, p = 0.01),
in vivo displayed favorable anti-tumor effect. The results demonstrated that mice treated with \(5i\). The results demonstrated that upon \(5i\) treatment, CDK4 and CyclinD1 were down-regulated, while P27 was up-regulated respectively (Fig. 2c, right). However, \(5i\) could not induce G1 cell cycle arrest in H1975 cells (Fig. S2c). To dissect the underlying mechanism of compound \(5i\), we conducted western blot assays. The results revealed that upon \(5i\) treatment, CDK4 and CyclinD1 were down-regulated, while P27 was up-regulated respectively (Fig. 2c, right). However, \(5i\) could not induce G1 cell cycle arrest in H1975 cells (Fig. S2c).

To unveil the role of autophagy in \(5i\) induced cell viability inhibition and G1 cell cycle arrest. To evaluate the anti-lung cancer activity of compound \(5i\) in vivo, A549-luciferase cells (1 × 10^6) were intravenously injected into SCID/Beige mice (n = 6 for each group). Vehicle, \(5i\) (10, 20 mg/kg), and matrine (20 mg/kg) were intraperitoneally administered every other day for 3 weeks. The results demonstrated that \(5i\) significantly suppressed tumor growth reflected by decrease of luciferase bioluminescence intensity, while matrine had no obvious effect (Fig. 5a,b). Besides, \(5i\) treatments did not lead to body weight reduction (Fig. 5c). Tumor can be obviously found in the dissected lung tissue of vehicle and matrine group, while in \(5i\) group, tumor size decreased dramatically in a dose-dependent manner (Fig. 5d).

Suppression of autophagy attenuates compound \(5i\) induced cell viability inhibition and G1 cell cycle arrest. To further dissect the underlying molecular mechanism of compound \(5i\) induced autophagy, we detected the \(PI3K/AKT/mTOR\) pathway in H460, A549, and H1975 lung cancer cells upon \(5i\) treatment. The results showed that with treatment of compound \(5i\), the \(PI3K/AKT/mTOR\) pathway was down-regulated in both H460 and A549 lung cancer cells in a dose-dependent manner (Fig. 3c), but not in H1975 lung cancer cells (Fig. S2e).

### Table 1. Anti-proliferative activities of target compounds in human cancer cell lines.

| Compounds | SGC-7901 IC50 (μM) | MCF-7 IC50 (μM) | A549 IC50 (μM) | Bel-7402 IC50 (μM) |
|-----------|---------------------|----------------|----------------|-------------------|
| \(5a\)    | 58.5 ± 4.2          | 81.7 ± 1.2     | 83.2 ± 5.6     | 61.4 ± 7.7        |
| \(5b\)    | 47.3 ± 4.5          | 35.2 ± 3.8     | 68.9 ± 11.5    | 55.8 ± 4.1        |
| \(5c\)    | 13.2 ± 2.8          | 14.2 ± 3.2     | 18.0 ± 4.2     | 15.6 ± 8.4        |
| \(5d\)    | 71.8 ± 5.8          | 82.9 ± 1.9     | >100           | 69.4 ± 5.1        |
| \(5e\)    | 52.8 ± 2.0          | 59.9 ± 4.0     | 70.3 ± 9.1     | 63.1 ± 6.3        |
| \(5f\)    | 30.3 ± 2.6          | 33.8 ± 2.5     | 38.4 ± 2.8     | 27.8 ± 3.1        |
| \(5g\)    | 26.7 ± 2.1          | 29.2 ± 1.8     | 34.7 ± 4.2     | 32.2 ± 3.5        |
| \(5h\)    | 55.2 ± 3.7          | 53.4 ± 4.5     | 65.1 ± 7.1     | 71.1 ± 6.7        |
| \(5i\)    | 9.4 ± 1.9           | 7.3 ± 0.5      | 8.1 ± 0.3      | 7.6 ± 0.8         |
| \(5j\)    | 63.3 ± 4.6          | 55.5 ± 5.4     | 89.9 ± 9.6     | 63.7 ± 4.9        |
| \(5k\)    | 40.9 ± 3.7          | 55.1 ± 5.3     | 60.2 ± 5.4     | 63.8 ± 4.9        |
| \(5l\)    | 88.0 ± 8.2          | 90.1 ± 6.2     | >100           | 87.8 ± 9.7        |
| \(5m\)    | 62.4 ± 4.2          | 45.2 ± 4.4     | 86.8 ± 7.6     | 64.7 ± 7.5        |
| \(5n\)    | 94.9 ± 4.8          | 99.1 ± 5.6     | >100           | 88.2 ± 5.9        |
| \(5o\)    | 87.7 ± 7.8          | 62.2 ± 3.9     | 94.7 ± 9.2     | 74.3 ± 8.5        |
| \(5p\)    | 76.2 ± 6.0          | 56.1 ± 3.6     | 93.5 ± 10.1    | 63.1 ± 5.9        |
| \(5q\)    | 39.9 ± 1.9          | 33.3 ± 1.9     | 52.9 ± 2.5     | 40.8 ± 2.2        |
| matrine   | 1380 ± 116          | 2497 ± 208     | 3923 ± 243     | 2057 ± 192        |

Note: IC50 values are taken as a mean from 3 experiments. Mean ± SD.
Discussion

Matrine is a highly polar basic compound and used in the treatment of hepatitis and hepatic fibrosis in China for a long time with low toxicity. Recently, the anticancer effects of matrine have become attractive for its broad anticancer spectrum and good safety. Besides, clinical studies have demonstrated that the quality of life and immune function of cancer patients were largely improved by combining standard therapies with the use of matrine. However, the low bioavailability of matrine has limited its use as an anticancer drug. In virtue of its favorable safety and low bioactivity, we designed and synthesized 17 matrine derivatives bearing benzo-\(\alpha\)-pyrone structure which appears as a core skeleton in many anticancer compounds. The results of in vitro cytotoxic
activity assays indicated that most of the target compounds showed improved anticancer effects with IC50 15–484 times lower than that of matrine in four tested human cancer cell lines (Table 1). Compound 5i exhibited the most potent anticancer effects. Moreover, compound 5i inhibited lung cancer cell proliferation in vitro and in vivo (Fig. 2a, Fig. S2a, and Fig. 5a,b). Interestingly, in our previous study, we discovered that matrine derivative 6i bearing p-methoxyphenyl structure also showed strong anticancer effect in A549 lung cancer cell lines (IC50 = 1.6 μM), but displayed toxicity in the in vivo mouse model. Compared with 6i, compound 5i of this study displayed no obvious side effects reflected by body weight loss and ALT, AST and Cr detection (Fig. 5c,f–h). These results implied that compound 5i displayed advantage in drug safety and druggable potential.

Epidermal growth factor receptor (EGFR) mutation plays an oncogenic role in lung cancer initiation. Lung cancer patients with EGFR mutation accounts for 10% of non-small cell lung cancer (NSCLC) in United States and about 40% of NSCLC in East Asia. Thus, tyrosine kinase inhibitors (TKIs) specific for EGFR (EGFR-TKIs) have become a main focus in lung cancer therapy. The efficiency of first-generation EGFR-TKIs, such as gefitinib, could reach 70–80% in NSCLC patients harboring EGFR mutations (exon 19 deletion and L858R). However, patients gradually develop acquired resistance to EGFR-TKIs within 12 months. The most common mechanism of resistance is a second mutation of EGFR (T790M), which accounts for 50% of all resistance cases and results in the continued activation of PI3K/AKT pathway. Thus, the therapeutic strategies for lung cancer patients with EGFR wild type, first mutation, or acquired mutation could be different. In this study, we discovered that compound 5i could not only inhibit the proliferation of A549 and H460 lung cancer cells (EGFR wild type) but also H1975 lung cancer cells (EGFR acquired mutation, L858R and T790M mutation) (Fig. 2a, Fig. S2a). However, compound 5i could induce G1 cell cycle arrest and autophagy and attenuate PI3K/AKT pathway in A549 and H460 lung cancer cells (Fig. 2c, Fig. S2c–e) but not in H1975 lung cancer cells (Fig. S2c–e). The anti-proliferative activity mechanism of 5i on EGFR wild type lung cancer cells and EGFR double mutation lung cancer cells might be different. Thus, the anti-proliferative effects mechanism of 5i on H1975 lung cancer cells needs further investigated.

Autophagy is a cellular process whereby the cell degrades subcellular materials to generate energy. To our best knowledge, autophagy plays a paradoxical role in cancer development. Inactivation of autophagy-specific genes (beclin1, atg5) resulted in increased tumorigenesis while activation of autophagy may help cancer cells survive in nutrient-limited environments. Therefore, it is important to distinguish between cytoprotective and cytotoxic autophagy. In this study, we found that compound 5i could induce autophagy in lung cancer cells (Fig. 3). Moreover, suppression of autophagy with 3-MA attenuated 5i induced cell viability inhibition (Fig. 4c). These results indicated that autophagy played a cytotoxic role in compound 5i induced lung cancer cell viability...
inhibition. PI3K/Akt pathway is abnormally activated in many malignancies (such as gastric, breast and hepatic cancer), which could turn autophagy off20. Also, PI3K/Akt pathway plays a vital role in cancer cell proliferation. In this study, we discovered that compound 5i could dramatically down-regulated PI3K/Akt pathway. Considering abnormal activities of PI3K/Akt pathway in cancer and the inhibition effects of 5i on PI3K/Akt pathway, we could infer that 5i exhibited its pan anticancer effects by inhibiting PI3K/Akt pathway activities.

In conclusion, we synthesized 17 matrine derivatives which showed improved anticancer activities towards cancer cell lines. Compound 5i displayed the strongest anticancer activity which inhibited lung cancer cell proliferation in vitro and in vivo with no obvious side effects. Further studies indicated that compound 5i arrested cell cycle at G1 phase and induced autophagy in lung cancer cells. Moreover, compound 5i could down-regulate PI3K/Akt pathway and suppression of autophagy attenuated 5i induced proliferation inhibition. Our studies suggested that matrine derivative 5i could be a potential effective compound to treat lung cancer.

Methods

General procedure of matrine derivatives synthesis. Firstly, matrine was hydrolyzed with aqueous potassium hydroxide to produce matrine acid (intermediate 2). Then in the presence of triethylamine (Et3N), intermediate 3 was prepared via the reaction of intermediate 2 with di-tert-butyl dicarbonate ((Boc)2O) in the reflux of methanol31. Intermediate 4 was obtained through the reaction of intermediate 3 with corresponding salicylaldehydes by mixed anhydrides method using 4-dimethylaminoxide (DMAP) as catalyst32. In this step, 4-hydroxy salicylaldehyde was selectively protected by methoxymethyl ether33. Products 5a~h were prepared via intramolecular aldol reaction with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in refluxing anhydrous toluene34. In view of natural prevalently occurring N-oxidation in quinolizidine alkaloid, derivatives 5i~k were synthesized by converting products 5c~e to their N-oxide forms with 3-chloroperbenzoic acid (m-CPBA) in ice-cold chloroform. Derivatives 5l~q were produced by removing the N-Boc structure from their corresponding products 5 in hydrochloric acid methanol solution rather than trifluoroacetic acid/dichloromethane concerning to the lactone stability. Under this acidic condition, the protection group methoxymethyl ether of 5d was dropped off along with N-Boc, giving the corresponding phenolic compound. All reagents and solvents were purchased from commercial sources. Further purification and drying by standard methods were employed when necessary. For thin layer chromatography (TLC) analysis Qingdao haiyang GF254 silica gel plates were used. Column chromatography was carried out using Qingdao haiyang 300–400 mesh silica gel. All NMR spectra were recorded on Bruker AVANCE 600 spectrometers operating at 1H and 13C frequencies of 600.17 and 150.91 MHz, respectively, using DMSO-d6 or CDCl3 as solvent. Chemical shifts (δ) are in ppm relative to the residual solvent signal (DMSO-d6 with 2.49 and 39.52 ppm and CDCl3 with 7.26 and 77.16 ppm for 1H and 13C, respectively). The coupling constant (J) was presented in hertz (Hz). Electrospray ionization mass spectra (ESI-MS) were recorded on a Thermo Scientific TSQ Quantum Access Max mass spectrometer.

Figure 5. In vivo anti-lung cancer effects of 5i. (a) The mice were detected by IVIS Spectrum. (b) The relative luciferase intensity in the mice. (c) The body weight of mice was monitored every two days. (d) Representative images of dissected lung tissue from each group. (e) Hematoxylin and eosin (HE) staining of lung tissue sections of mice from each group. (f–h) The serum ALT (f), Cr (g), and AST (h) levels were detected of mice from each group. Data are represented as mean ± SD and p value was calculated with t-test.
Cell culture, cell proliferation and cell viability assays. Human cancer cell lines used in this study were purchased from ATCC (American Type Culture Collection) and cultured in DMEM high-glucose (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were cultured at 37 °C in an atmosphere of 95% air and 5% CO2 under humidified condition. For MTT assay, cells (3000 cells per well) were plated in flat-bottomed 96-well micro plates. Sixteen hours after seeding, new medium containing different concentrations of target compounds or solvent control (DMSO) was added. Cells were further incubated for indicated times and incubated with MTT for additional 2–4 hours. The plates were then assayed by testing the absorbance at 490 nm. Cell viability was estimated by trypan blue dye exclusion assay.

Clonogenic assay and cell cycle analysis. For clonogenic assay, the cells were suspended in 1 ml DMEM containing 0.3% low-melting-point agarose (Amresco, Solon, OH) and 10% FBS, and plated on a bottom layer containing 0.6% agarose and 4 μM 5i in 35 mm plates (1000 cells/plate). After 14 days of culture, cells were stained with Giemsa and clones containing more than 50 cells were counted. For cell cycle analysis, the cells were treated with 5i at different concentrations for 24 hours. Then cells were digested with 0.25% trypsin and washed with cold PBS for 2–3 times. Later, cells were fixed with 70% ethanol at −20 °C overnight. DNA content was determined by PI staining and flow cytometry analysis.

Immunofluorescence analysis. Cells (2 × 10^5 per well) were seeded on cover-slips with 1% gelatin in 6-well culture plates and treated with 5i (2, 4 and 6 μM) for 24 hours. The cells were then washed with cold PBS and fixed with 4% paraformaldehyde at room temperature for 15 min. Then cells were washed and blocked by incubating with 5% BSA (Ameresco, USA) in PBS and incubated with an anti-LC3 antibody overnight at 4 °C, followed by incubation with a FITC-conjugated secondary antibody for 2 hours at room temperature in a dark humid chamber. Following washed with Tween-20/PBS for 3 times, the cover-slips were inverted on the glass slides. The cells were observed under the confocal microscope (Zeiss LSM 510 Meta).

ELISA. Mouse blood was obtained before cervical dislocation. Serum was separated by centrifugation at 2000 g and concentration of ALT, Cr, and AST in serum of mice was determined by ELISA using commercially available ELISA kit (TSZ) according to the manufacture instructions. The absorbance of the plates was read at 450 nm using an automated microplate reader (Bio-Tek, Winooski, VT, USA).

Western blotting. Cells were lysed in RIPA buffer supplemented with protease inhibitors. Proteins (20 μg) were subjected to 6–15% SDS-PAGE, electrophoresed and transferred on to a nitrocellulose membrane. After blocking with 5% non-fat milk in Tris-buffered saline, the membrane was washed and incubated with the indicated primary and secondary antibodies and detected using the Luminescent Image Analyser LSA 4000 (GE, Fairfield, CO, USA).

Murine models. The animal studies were approved by the Institutional Review Board of Institute of Zoology, Chinese Academy of Sciences. All animal studies were conducted according to protocols approved by the Animal Ethics Committee of the Institute of Zoology, Chinese Academy of Sciences. SCID/beige mice were injected with A549-luciferase (A549-Luc) cells (1 × 10^6) via tail vein, and 4 days later the mice were randomized into 4 groups to receive treatment with intraperitoneal injection of vehicle, matrine at 20 mg/kg, 5i at 10 and 20 mg/kg (n = 6 for each group; once every two days for 21 days). The mice were imaged by IVIS Spectrum at day 21, and were euthanized by cervical dislocation.

Statistical analysis. The data are presented as the mean ± SD of three independent experiments. Differences between data groups were evaluated for significance using Student’s t-test of unpaired data (two-tailed). P values less than 0.05 were considered statistically significant in all cases.

References
1. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer. WHO Press, 2015. Adv Nutr 7, 418–419 (2016).
2. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N Engl J Med 359, 1367–1380 (2008).
3. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129–2139 (2004).
4. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
5. Guan, C. N., Cai, L. Z., Yue, L. Q. & Zhang, Y. Clinical study on treatment of advanced primary liver cancer by Y anshu injection combining with chemotherapy. Zhonggu Zhong Yao Za Zhi 31, 510–512 (2006).
6. Liu, J. & Liu, Y. Influence of erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer. J Tradit Chin Med 33, 303–306 (2013).
7. Sun, M. et al. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med 2012, 373219 (2012).
8. Sun, Q. et al. Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr J Tradit Complement Altern Med 9, 178–188 (2012).
9. Wang, C. Y., Bai, X. Y. & Wang, C. H. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med 42, 543–559 (2014).
10. Wei, R. et al. Efficacy of Yanshu injection (a compound Chinese traditional medicine) combined with concurrent radiochemotherapy in patients with stage III nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Za Zhi 33, 391–394 (2011).
11. Liu, Y. et al. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 35, 5111–5119 (2014).
12. Wu, L. et al. Synthesis and biological evaluation of matrine derivatives as anti-hepatocellular cancer agents. Bioorg Med Chem Lett 26, 4267–4271 (2016).
13. Hu, P. Y. et al. Pharmacokinetics and distribution of sophoridine nanoliposomes in rats. Chinese Journal of New Drugs 21, 2662–2666 (2012).
14. Li, Y. et al. High-performance liquid chromatographic method for simultaneous determination of sophoridine and matrine in rat plasma. Biomed Chromatogr 18, 619–624 (2004).
15. Ye, G. et al. LC-MS characterization of efficacy substances in serum of experimental animals treated with Sophora flavescens extracts. Biomed Chromatogr 21, 655–660 (2007).
16. Wang, L. et al. Synthesis, characterization and in vitro anti-tumor activities of matrine derivatives. Bioorg Med Chem Lett 22, 4100–4102 (2012).
17. Lacy, A. & O’Kennedy, R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 10, 3797–3811 (2004).
18. Levine, B. Cell biology: autophagy and cancer. Nature 446, 745–747 (2007).
19. Nys, K., Agostinis, P. & Vermeire, S. Autophagy: a new target or an old strategy for the treatment of Crohn’s disease? Nature reviews. Gastroenterology & hepatology 10, 395–401 (2013).
20. Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193–204 (2004).
21. Liu, J. Y. et al. Effect of matrine on the expression of substance P receptor and inflammatory cytokines production in human skin keratinocytes and fibroblasts. Int Immunopharmacol 7, 816–823 (2007).
22. Jiang, H. et al. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 559, 98–108 (2007).
23. Li, H. et al. Therapeutic effects of matrine on primary and metastatic breast cancer. Adv Chin Med 38, 1115–1130 (2010).
24. Liu, T., Song, Y., Chen, H., Pan, S. & Sun, X. Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull 33, 1740–1745 (2010).
25. Chen, J. et al. Effects of matrine injection on T-lymphocyte subsets of patients with malignant tumor after gamma knife radiosurgery. Journal of Chinese integrative medicine 4, 78–79 (2006).
26. Huang, S., Fan, W., Liu, P. & Tian, J. Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer. Zhongguo Zhong Yao Za Zhi 36, 3198–3202 (2011).
27. Metro, G. & Crino, L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 1, 5–13 (2012).
28. Pao, W. et al. EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306–13311 (2004).
29. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nature reviews. Cancer 7, 169–181 (2007).
30. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786–792 (2005).
31. Tian, X. et al. Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett 16, 1721–1725 (2006).
32. DeWit, M. A. & Gillies, E. R. Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-imnomilative spacers. Org Biomol Chem 9, 1846–1854 (2011).
33. Greene’s protective groups in organic synthesis. Choice: Current Reviews for Academic Libraries 44, 1562–1562 (2007).
34. Chun, K. et al. Chromone-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem 16, 530–535 (2008).
35. Wu, L. et al. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep 34, 3311–3317 (2015).
36. Wu, L. C. et al. Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells. ACS Med Chem Lett 4, 921–926 (2013).
37. Zhou, G. B. et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109, 3441–3450 (2007).

Acknowledgements
The present study was financially supported by the Natural Science Foundation of China (No. 21262005), the high level innovation team and outstanding scholar project of Guangxi institutions of higher education (gui jiao ren [2014] 49 hao), the Postdoctoral Science Foundation of Guangxi Province of China (Y304001912), the National Natural Science Funds for Distinguished Young Scholar (81425025), and Special Financial Grant from the China Postdoctoral Science Foundation (2016T90135). We thank Professor Hu Tingjun of School of Zoology Science and Technology of Guangxi University for the experimental support.

Author Contributions
The project was conceived by L.S.W. and G.Z. The experiments were designed by L.S.W. and L.C.W. The experiments were conducted by L.C.W., G.W., J.W., S.L. and S.Z. Data were analyzed by L.C.W., J.W. and M.L. The manuscript was written by L.C.W. and L.S.W.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wu, L. et al. Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents. Sci. Rep. 6, 35918; doi: 10.1038/srep35918 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2016